Back to Journals » Drug Design, Development and Therapy » Volume 12

The oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluation

Authors Chen N, Yang X, Guo C, Bi X, Chen J, Chen H, Li H, Lin H, Zhang Y

Received 14 September 2017

Accepted for publication 14 November 2017

Published 28 December 2017 Volume 2018:12 Pages 57—65


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Frank M. Boeckler

Ning Chen,1 Xiao-yan Yang,1,2 Chang-e Guo,1 Xin-ning Bi,1 Jian-hua Chen,1 Hong-ying Chen,1 Hong-pin Li,1 Hong-ying Lin,1 Yu-jie Zhang1

1School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 2Nanjing Sanhome Pharmaceutical Co., Ltd., Nanjing, China

Abstract: Epiberberine (EPI) is a novel and potentially effective therapeutic and preventive agent for diabetes and cardiovascular disease. To evaluate its potential value for drug development, a specific, sensitive and robust high-performance liquid chromatography-tandem mass spectrometry assay for the determination of EPI in rat biological samples was established. This assay was used to study the pharmacokinetics, bioavailability and excretion of EPI in rats after oral administration. In addition, a cocktail method was used to compare the inhibition characteristics of EPI on cytochrome P450 (CYP450) isoforms in human liver microsomes (HLMs) and rat liver microsomes (RLMs). The results demonstrated that EPI was rapidly absorbed and metabolized after oral administration (10, 54 or 81 mg/kg) in rats, with Tmax of 0.37–0.42 h and T1/2 of 0.49–2.73 h. The Cmax and area under the curve values for EPI increased proportionally with the dose, and the oral absolute bioavailability was 14.46%. EPI was excreted mainly in bile and feces, and after its oral administration to rats, EPI was eliminated predominantly by the kidneys. A comparison of the current half-maximal inhibitory concentration and Ki values revealed that EPI demonstrated an obvious inhibitory effect on CYP2C9 and CYP2D6. Furthermore, its effect was stronger in HLM than in RLM, more likely to be a result of noncompetitive inhibition.

Keywords: epiberberine, bioavailability, excretion kinetics, CYP inhibition type

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]